Adipokines in patients with hypertensive disease with obesity in the dynamics of combined antihypertensive therapy

  • P. G. Kravchun Kharkiv National Medical University
  • O. I. Kadykova Kharkiv National Medical University
  • U. S. Herasymchuk Kharkiv National Medical University
Keywords: adiponutrin; galanin; blood pressure; body mass index; enalapril; valsartan.


Hypertensive disease today is one of the most common cardiovascular diseases, as well as the most common disease associated with obesity. Evaluation of the level of adipokines, namely adiponutrin and galanin, depending on the degree and duration of hypertension, the degree of obesity and their correction against the background of combined antihypertensive therapy is relevant for further understanding of this comorbidity and improvement of the early diagnostics. 127 people were examined, including 107 patients with hypertension of degree 1–3 and 20 healthy persons. Of the patients included in the study, the adiponutrin and the galanin levels were determined in 58 patients, out of which 22 were prescribed different regimens of combined antihypertensive therapy. To determine the level of adiponutrin and galanin, an enzyme-linked immunosorbent assay was used. A significant increase was found in the blood serum of the examined adipokines in comparison with the control group: the galanin level was 4.8 times higher than in the control group, the adiponutrin level in patients with this comorbid pathology was 3.3 times higher than that in the control group. The galanin level is most pronounced in patients with hypertension of degree 3 and obesity of degree 3, which is confirmed by the presence of a direct correlation with systolic, diastolic and pulse blood pressure, very low density lipoprotein cholesterol. The adiponutrin level in the blood serum increased correspondingly to the increase in body mass index: in patients with obesity of degree 3 it was 15.8 times higher than this indicator in patients with normal body weight, 8.8 times higher than in patients with overweight, 6.1 times higher than in patients with obesity of degree 1 and 2.5 times higher than in patients with obesity of degree 2. The levels of the studied adipokines in patients differed also relative to the duration of hypertension. There was a 1.8-, 5.1-, 5.2-fold increase (respectively, ≤5, 6–10, >10 years) of the galanin content in the blood serum compared to the control group. Also an increase of the serum adiponutrin level was noted in comparison with the control group. Against the background of combined antihypertensive therapy, we observed favourable dynamics of galanin and adiponutrin. It is important to conduct further studies to assess the activity of galanin and adiponutrin with a longer follow-up period in wider populations.


Abraham, H. M. A., White, C. M., & White, W. B. (2014). The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Safety, 38(1), 33–54.

Acar, S., Paketçi, A., Küme, T., Demir, K., Çalan, Ö. G., Böber, E., & Abaci, A. (2018). Positive correlation of galanin with insulin resistance and triglyceride levels in obese children. Turkish Journal of Medical Sciences, 48(3), 560–568.

Asarian, L., & Geary, N. (2013). Sex differences in the physiology of eating. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 305(11), R1215–R1267.

Baranowska, B., Radzikowska, M., Wasilewska-Dziubinska, E., Roguski, K., & Borowiec, M. (2000). Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Diabetes, Obesity and Metabolism, 2(2), 99–103.

Barson, J. R., Morganstern, I., & Leibowitz, S. F. (2013). Galanin. Handbook of Biologically Active Peptides, 1097–1103.

Benz, J. R., Black, H. R., Graff, A., Reed, A., Fitzsimmons, S., & Shi, Y. (1998). Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. Journal of Human Hypertension, 12(12), 861–866.

Bhaskar, S. V., Gupta, R. K., & Kumar, M. K. (2017). Body fat composition as a marker for risk assessment in hypertension. Journal of Marine Medical Society, 19(1), 34.

Black, H. R., Graff, A., Shute, D., Stoltz, R., Ruff, D., Levine, J., Shi, Y., & Mallows, S. (1997). Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. Journal of Human Hypertension, 11(8), 483–489.

Chandra, A., Neeland, I. J., Berry, J. D., Ayers, C. R., Rohatgi, A., Das, S. R., Khera, A., McGuire, D. K., Lemos, J. A., & Turer, A. T. (2014). The relationship of body mass and fat distribution with incident hypertension. Journal of the American College of Cardiology, 64(10), 997–1002.

Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., Wang, S., Fortier, M., Greenberg, A. S., & Obin, M. S. (2005). Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. Journal of Lipid Research, 46(11), 2347–2355.

DeMarco, V. G., Aroor, A. R., & Sowers, J. R. (2014). The pathophysiology of hypertension in patients with obesity. Nature Reviews Endocrinology, 10(6), 364–376.

Fang, P., Bo, P., Shi, M., Yu, M., & Zhang, Z. (2013). Circulating galanin levels are increased in patients with gestational diabetes mellitus. Clinical Biochemistry, 46(9), 831–833.

Fang, P., He, B., Shi, M., Kong, G., Dong, X., Zhu, Y., Bo, P., & Zhang, Z. (2015). The regulative effect of galanin family members on link of energy metabolism and reproduction. Peptides, 71, 240–249.

Fang, P., Yu, M., Shi, M., Zhang, Z., Sui, Y., Guo, L., & Bo, P. (2012). Galanin peptide family as a modulating target for contribution to metabolic syndrome. General and Comparative Endocrinology, 179(1), 115–120.

Forouzanfar, M. H., Liu, P., Roth, G. A., Ng, M., Biryukov, S., Marczak, L., Alexander, L., Estep, K., Abate, K. H., Akinyemiju, T. F., Ali, R., Alvis-Guzman, N., Azzopardi, P., Banerjee, A., Bärnighausen, T., Basu, A., Bekele, T., Bennett, D. A., Biadgilign, S., Catalá-López, F., Feigin, V. L., Fernandes, J. C., Fischer, F., Gebru, A. A., Gona, P., Gupta, R., Hankey, G. J., Jonas, J. B., Judd, S. E., Khang, Y.-H., Khosravi, A., Kim, Y. J., Kimokoti, R. W., Kokubo, Y., Kolte, D., Lopez, A., Lotufo, P. A., Malekzadeh, R., Melaku, Y. A., Mensah, G. A., Misganaw, A., Mokdad, A. H., Moran, A. E., Nawaz, H., Neal, B., Ngalesoni, F. N., Ohkubo, T., Pourmalek, F., Rafay, A., Rai, R. K., Rojas-Rueda, D., Sampson, U. K., Santos, I. S., Sawhney, M., Schutte, A. E., Sepanlou, S. G., Shifa, G. T., Shiue, I., Tedla, B. A., Thrift, A. G., Tonelli, M., Truelsen, T., Tsilimparis, N., Ukwaja, K. N., Uthman, O. A., Vasankari, T., Venketasubramanian, N., Vlassov, V. V., Vos, T., Westerman, R., Yan, L. L., Yano, Y., Yonemoto, N., Zaki, M. E. S., & Murray C. J. L. (2017). Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. The Journal of the American Medical Association, 317(2), 165.

Gopalakrishnan, L., Chatterjee, O., Raj, C., Pullimamidi, D., Advani, J., Mahadevan, A., & Keshava Prasad, T. S. (2020). An assembly of galanin–galanin receptor signaling network. Journal of Cell Communication and Signaling, 15(2), 269–275.

Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2015). Obesity-induced hypertension. Circulation Research, 116(6), 991–1006.

Hsieh, C.-J., Wang, P.-W., & Chen, T.-Y. (2014). The relationship between regional abdominal fat distribution and both insulin resistance and subclinical chronic inflammation in non-diabetic adults. Diabetology and Metabolic Syndrome, 6(1), &&&&&.

Huang, Y., He, S., Li, J. Z., Seo, Y.-K., Osborne, T. F., Cohen, J. C., & Hobbs, H. H. (2010). A feed-forward loop amplifies nutritional regulation of PNPLA3. Proceedings of the National Academy of Sciences, 107(17), 7892–7897.

Jacobs, M., van Greevenbroek, M. M. J., van der Kallen, C. J. H., Ferreira, I., Blaak, E. E., Feskens, E. J. M., Jansen, E. H. J. M., Schalkwijk, C. G., Stehouwer, C. D. A. (2009). Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: The CODAM study. European Journal of Clinical Investigation, 39(6), 437–444.

Junkerov, V. I., & Grigor’ev, S. G. (2002). Matematiko-statisticheskaja obrabotka dannyh medicinskih issledovanij [Mathematical and statistical processing of medical research data]. Voenno-Medicinskaja Akademija, Sankt-Peterburg (in Russian).

Kantartzis, K., Peter, A., Machicao, F., Machann, J., Wagner, S., Konigsrainer, I., Konigsrainer, A., Schick, F., Fritsche, A., Haring, H.-U., & Stefan, N. (2009). Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes, 58(11), 2616–2623.

Kovalenko, V. M., & Kornac'kyj, V. M. (2017). Problemy zdorov’ja i tryvalosti zhyttja v suchasnyh umovah [Health and life expectancy issues in modern conditions]. Kyiv (in Ukrainian).

Lacourcière, Y., Poirier, L., Hebert, D., Assouline, L., Stolt, P., Rehel, B., & Khder, Y. (2005). Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clinical Therapeutics, 27(7), 1013–1021.

Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd-Jones, D., & Sowers, J. (2012). Obesity-related hypertension: Pathogenesis, cardiovascular risk, and treatment. The Journal of Clinical Hypertension, 15(1), 14–33.

Lau, D. C. W., Dhillon, B., Yan, H., Szmitko, P. E., & Verma, S. (2005). Adipokines: Molecular links between obesity and atheroslcerosis. American Journal of Physiology-Heart and Circulatory Physiology, 288(5), H2031–H2041.

Leibowitz, S. F. (1998). Differential functions of galanin cell groups in the regulation of eating and body weight a. Annals of the New York Academy of Sciences, 863(1), 206–220.

Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., A AlMazroa, M., Amann, M., Anderson, H. R., & Andrews, K. G. (2012). A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. The Lancet, 380(9859), 2224–2260.

Liu, T., Wang, Q., Berglund, E. D., & Tong, Q. (2013). Action of neurotransmitter: A key to unlock the AgRP neuron feeding circuit. Frontiers in Neuroscience, 6, &&&&&.

Malacco, E., Vari, N., Capuano, V., Spagnuolo, V., Borgnino, C., Palatini, P., & Investigators, V.-S. (2003). A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: The Val-Syst study. Clinical Therapeutics, 25(11), 2765–2780.

Nakamura, K., Fuster, J. J., & Walsh, K. (2014). Adipokines: A link between obesity and cardiovascular disease. Journal of Cardiology, 63(4), 250–259.

Nobili, A., Garattini, S., & Mannucci, P. M. (2011). Multiple diseases and polypharmacy in the elderly: Challenges for the internist of the third millennium. Journal of Comorbidity, 1(1), 28–44.

Ogden, C. L., Carroll, M. D., Lawman, H. G., Fryar, C. D., Kruszon-Moran, D., Kit, B. K., & Flegal, K. M. (2016). Trends in obesity prevalence among children and adolescents in the united states, 1988–1994 through 2013–2014. The Journal of the American Medical Association, 315(21), 2292.

Palmer, C. N. A., Maglio, C., Pirazzi, C., Burza, M. A., Adiels, M., Burch, L., Donnelly, L. A., Colhoun, H., Doney, A. S., Dillon, J. F., Pearson E. R., McCarthy, M., Hattersley, A. T., Frayling, T., Morris, A. D., Peltonen, M., Svensson, P.-A., Jacobson, P., Borén, J., Sjöström, L., Carlsson, L. M. S., & Romeo, S. (2012). Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS One, 7(6), e39362.

Reisin, E., Graves, J. W., Yamal, J.-M., Barzilay, J. I., Pressel, S. L., Einhorn, P. T., Dart, R. A., Retta, T. M., Saklayen, M. G., & Davis, B. R. (2014). Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. Journal of Hypertension, 32(7), 1503–1513.

Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008). Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 40(12), 1461–1465.

Saleem, U., Khaleghi, M., Morgenthaler, N. G., Bergmann, A., Struck, J., Mosley, T. H., & Kullo, I. J. (2009). Plasma carboxy-terminal provasopressin (copeptin): A novel marker of insulin resistance and metabolic syndrome. The Journal of Clinical Endocrinology and Metabolism, 94(7), 2558–2564.

Seravalle, G., & Grassi, G. (2017). Obesity and hypertension. Pharmacological Research, 122, 1–7.

Speliotes, E. K., Butler, J. L., Palmer, C. D., Voight, B. F., GIANT Consortium the MIGen Consortium, NASH CRN, & Hirschhorn, J. N. (2010). PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology, 52(3), 904–912.

Sternson, S. M. (2011). Let them eat fat. Nature, 477(7363), 166–167.

Stojkovic, I. A., Ericson, U., Rukh, G., Riddestråle, M., Romeo, S., & Orho-Melander, M. (2014). The PNPLA3 Ile148Met interacts with overweight and dietary intakes on fasting triglyceride levels. Genes and Nutrition, 9(2), 388.

Sullivan, C. A., Kahn, S. E., Fujimoto, W. Y., Hayashi, T., Leonetti, D. L., & Boyko, E. J. (2015). Change in intra-abdominal fat predicts the risk of hypertension in japanese americans. Hypertension, 66(1), 134–140.

Sun, K., Kusminski, C. M., & Scherer, P. E. (2011). Adipose tissue remodeling and obesity. Journal of Clinical Investigation, 121(6), 2094–2101.

Tang, C. S., Zhang, H., Cheung, C. Y. Y., Xu, M., Ho, J. C. Y., Zhou, W., Cherny, S. S., Zhang, Y., Holmen, O., Au, K.-W., Yu, H., Xu, L., Jia, J., Porsch, R. M., Sun, L., Xu, W., Zheng, H., Wong, L.-Y., Mu, Y., Dou, J., Fong, C. H. Y., Wang, S., Hong, X., Dong, L., Liao, Y., Wang, J., Lam, L.S. M., Su, X., Yan, H., Yang, M.-L., Chen, J., Siu, C.-W., Xie, G., Woo, Y.-C., Wu, Y., Tan, K. C. B., Hveem, K., Cheung, B. M. Y., Zöllner, S., Xu, A., Chen, Y. E., Jiang, C. Q., Zhang, Y., Lam, T.-H., Ganesh, S. K., Huo, Y., Sham, P. C., Lam, K. S. L., Willer, C. J., Tse, H.-F., & Gao, W. (2015). Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. Nature communications, 6(1), 1–9.

The GBD 2015 Obesity Collaborators (2017). Health effects of overweight and obesity in 195 countries over 25 years. New England Journal of Medicine, 377(1), 13–27.

Trayhurn, P., & Wood, I. S. (2004). Adipokines: Inflammation and the pleiotropic role of white adipose tissue. British Journal of Nutrition, 92(3), 347–355.

Tsimikas, S., Willeit, J., Knoflach, M., Mayr, M., Egger, G., Notdurfter, M., Witztum, J. L., Wiedermann, C. J., & Kiechl, Q. X. S. (2008). Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: Results from the Bruneck study. European Heart Journal, 30(1), 107–115.

Valderas, J. M., Mercer, S. W., & Fortin, M. (2011). Research on patients with multiple health conditions: Different constructs, different views, one voice. Journal of Comorbidity, 1(1), 1–3.

Williams, B., & Mancia, G. (2018). Ten Commandments of the 2018 ESC/ESH HTN guidelines on hypertension in adults. European Heart Journal, 39(33), 3007–3008.

World Health Organization (2020). STEPS prevalence of noncommunicable disease risk factors in Ukraine 2019 (No. WHO/EURO: 2020-1468-41218-56060). World Health Organization, Regional Office for Europe.

How to Cite
Kravchun, P. G., Kadykova, O. I., & Herasymchuk, U. S. (2021). Adipokines in patients with hypertensive disease with obesity in the dynamics of combined antihypertensive therapy . Regulatory Mechanisms in Biosystems, 12(2), 362-368.